Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

By G. Sokos, L. Nikolaidis, S. Mankad, D. Elahi, R. Shannon. Journal of Cardiac Failure, 2006

651 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease (2017, background): “pancreatic beta cells by upregulation of glucokinase and glucose transporter 2 [43].”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, result): “Consistent with this study, long-term infusion of GLP-1 in patients with severe heart failure significantly improves left ventricular function, and the effect is also seen in patients with and without diabetes (Sokos et al., 2006).”
Incretin-based therapies for type 2 diabetes mellitus (2009, background): “Moreover, preliminary data from pilot studies in humans indicate that native GLP-1 may exert beneficial effects on heart failure”
Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways (2008, background): “Background—The glucagon-like peptide 1 receptor (GLP-1R) is believed to mediate glucoregulatory and cardiovascular effects of the incretin hormone GLP-1(7-36) (GLP-1), which is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) to GLP-1(9-36), a truncated metabolite generally thought to be inactive.”